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CYTOTOXIC EFFECTS OF BETULINIC ACID AND ITS DERIVATIVES ON 
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By 
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Chairman  : Prof Dr Abdul Manaf Ali, Ph. D  
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Betulinic acid (BA) is a triterpene from bark extracts of Melaleuca cajuputi Powell 
(Myretaceae) a Malaysian plant. The cytotoxic effects of  betulinic acid (BA) and its four 
synthetic derivatives that has been modified at C-3 hydroxy group of BA (betulinic acid 
acetate (BAAC), 3-O-(2’,2’-dimethylsuccinyl)-betulinic acid (BAES), 3-O-succinyl-
betulinic acid (BASUC) and betulinic acid benzoate (BCL) were screened on human 
myeloid leukemia (HL-60), human T4-lymphoblastoid (CEM-SS), BALB/c murine 
myelomonocytic leukemia (WEHI-3B), human cervical epithelial carcinoma (HeLa) 
human breast adenocarcinoma (MCF-7), mouse skin melanoma (B16), human 
glioblastoma (DBTRG0.5MG) cancer cell lines. Several derivatives elicited cytotoxicity 
as assessed by 3-[4,5-dimethylthizol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) 
assay. Betulinic acid acetate (BAAC) was the most effective among the betulinic acid 
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derivatives. It had the most potent cytotoxic activity against human myeloid leukemia 
(HL-60), human T4-lymphoblastoid (CEM-SS), BALB/c murine myelomonocytic 
leukemia (WEHI-3B) and human cervical epithelial carcinoma (HeLa) but not on normal 
human lymphocytes (PBMC), suggesting its action is specific for tumor cells. This study 
was focused on HL-60 that showed the most sensitive cell line after 72 hours of treatment 
with all betulinic acid derivatives. BA and BAAC inhibit HL-60 cell line after 72 hours 
treatment with IC50 values of 2.60 and 1.38 μg/mL, respectively. On microscopic 
examination, both compounds exhibited characteristic morphological features of 
apoptosis, such as cell shrinkage and formation of apoptotic bodies. Fluorescent staining 
with acridine orange (AO) and propidium iodide (PI) revealed distinct chromatin 
condensation and nuclear fragmentation. The internucleosomal DNA fragmentation was 
confirmed by the pattern of   DNA laddering into fragments with multiples of 180-220 
base pairs detected in agarose gel electrophoresis. The induction of apoptosis was also 
confirmed by flow cytometric analysis of the cell cycle. BA and BAAC were shown to 
induce a time dependent increase in the sub G1 peak indicating apoptotic phenomenon as 
obtained from the DNA content histogram analysis. BA and BAAC were marked as 
cytotoxic agent induced by apoptosis. 
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Betulinik acid (BA) merupakan sebatian triterpen yang diekstrak daripada Melaleuca 
cajuputi Powell sejenis tumbuhan di Malaysia. Kesan sitotoksik bagi betulinik asid (BA) 
dan empat sebatian terbitan sintetiknya yang telah diubahsuai pada C-3 kumpulan 
hidroksi  bagi BA (betulinik asid acetat (BAAC), 3-O-(2’,2’-dimetilsuccinil)-betulinik 
asid (BAES), 3-O-succinil-betulinik asid (BASUC) dan betulinik asid benzoat (BCL) 
telah diuji terhadap jujukan sel-sel kanser iaitu sel leukemia meilositik manusia (HL-60), 
leukemia T-limfoblastik manusia (CEM-SS), leukemia meilomonositik tikus (WEHI-3B), 
kanser servik epitelial manusia (HeLa), kanser payudara manusia (MCF-7), kanser kulit 
tikus (B16) dan kanser otak glioblastoma manusia  (DBTRG0.5MG). Asai 3-[4,5-
dimetiltizol-2-il]-2,5-difeniltetrazolium bromida (MTT) menunjukkan beberapa sebatian 
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terbitan mempamerkan kesan ketoksikan. Betulinik asid asitat (BAAC) merupakan 
sebatian yang paling efektif di antara sebatian terbitan betulinik asid yang lain. Sebatian 
ini mempunyai kesan ketoksikan yang sangat berpotensi terhadap leukemia meilositik 
manusia (HL-60), leukemia T-limfoblastik manusia (CEM-SS), leukemia meilomonositik 
tikus (WEHI-3B), kanser servik epitelial manusia (HeLa) dan tiada kesan sitoktoksik 
pada sel darah periferi manusia (PBMC), menunjukkan bahawa sebatian ini hanya 
bertindak pada sel kanser sahaja. Kajian ini telah ditumpukan pada HL-60 yang 
merupakan jujukan sel yang paling sensitif selepas 72 jam rawatan dengan semua 
sebatian terbitan betulinik asid. BA dan BAAC merencatkan pertumbuhan jujukan sel 
HL-60 selepas 72 jam rawatan dengan nilai IC50 masing-masing pada 2.60 and 1.38 
μg/mL. Kedua-dua sebatian ini menunjukkan ciri-ciri apoptosis seperti pengecutan sel 
dan pembentukkan badan apoptotik apabila dilihat melalui mikroskop. Pembahagian 
kondensasi kromatin dan pemecahan nuclear telah dilihat melalui pewarnaan fluoresen 
akridin oren (AO) dan propidium iodin (PI). Pemecahan DNA internukleosom telah 
disahkan oleh pembentukan tangga DNA kepada serpihan dengan susunan 180 – 220 bp 
dikesan pada gel agaros elektroforesis. Penentuan apoptosis ini juga telah dikenalpasti 
pada kitaran sel menggunakan analisis flow sitometrik. Peningkatan puncak sub G1 pada 
BA dan BAAC bergantung pada masa menerangkan fenomena apoptotik seperti yang 
dihasilkan oleh kandungan DNA pada analisis histogram. BA dan BAAC telah ditandai 
sebagai agen sitotoksik yang dicetuskan oleh apoptosis. 
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      CHAPTER 1 
 
INTRODUCTION 
 
Pentacyclic triterpenes have a wide spectrum of biological activities and some of 
them may be useful in medicine (Akihisa et al., 1996). Betulinic acid (3β-hydroxy-lup-
20(29)-ene-28-oic acid), an example of a pentacyclic triterpene is widely distributed in 
plant kingdom (Maurya et al., 1989). This compound can be chemically derived from 
betulin, a substance found in the outer bark of white birch tree Betula alba (Pisha et al., 
1995). Some biological activities have been ascribed to betulinic acid, with includes anti-
inflammatory, anti-tumor (Mukherjee et al., 1997), anti-viral (De Clercq, 1995), anti-
neoplastic (Fulda et al., 1999) and anti-plasmodial (Ziegler et al, 2004).  
 
 Betulinic acid exerts a selective anti-tumor activity on cultured human melanoma 
(MEL-2) cells (Pisha et al., 1995) and malignant brain tumor (Fulda et al., 1999). This 
compound also showed inhibitory effect on leukemia (HL-60, U937 and K562) and 
neuroblastoma (GOTO and NB-1) cell growth (Hata et al., 2003). BA has been 
specifically kills neuroectodermal tumor cells (Fulda et al., 1997). The studies on human 
neuroblastoma (SHEP) cell line have revealed that BA acts on mitochondria without 
affecting cell surface receptor and induced apoptosis in cells, but not in lymphoid cell 
lines (Fulda et al., 1998). The anti-tumor activity of betulinic acid has been reported to 
other human neoplastic cell lines including lung carcinomas, ovarian and cervical 
carcinomas (Zuco et al., 2002).  
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 The anti-viral properties of betulinic acid were also confirmed in clinical trials 
(De Clercq, 2000). Betulinic acid also has antiviral properties against influenza A and 
herpes simplex type 1 (HSV-1, strain 1C) viruses in vitro (Baltina et al., 2003). Betulinic 
acid has also been shown to suppress ECHO 6 virus reproduction (Pavlova et al., 2003). 
The isolated betulinic acid from leaves of Syzigium claviflorum (Mytaceae), exhibited 
inhibitory activity against human immunodeficiency virus type 1 (HIV-1) replication in 
H9 lymphocyte cells (Fujioka et al., 1994).  
 
Betulinic acid has been known to induce apoptosis selectively in tumor cells lines, 
but not on normal cell lines (Zuco et al., 2002). The favorable therapeutic index from the 
lack of toxicity towards normal cells suggested betulinic acid to be an attractive and 
promising anti-tumor agent (Pisha et al., 1995). This feature makes betulinic acid unique 
in comparison to compounds that are currently used in cancer therapy, such as taxol, 
camptothecin, elipticine, etoposide, vinblastine and vincristine. All these anti-tumor 
compounds are very toxic and inhibit replication of both cancer and normal cells (Zuco et 
al., 2002). 
 
In this project, the potential of betulinic acid isolated from a Malaysian plant as an 
anti-cancer agent on human myeloid leukemia cell line will be investigated. Here, the in 
vitro cytotoxic activity of betulinic acid and its derivatives will be assessed using 
leukemic cell lines and compared with conventional anti-neoplastic drug (doxorubicin).  
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Therefore, the objectives of this study are: 
 
1. To determine the cytotoxic effect of betulinic acid and betulinic acid derivatives 
on different cancer cell lines. 
2. To determine the IC50 values of betulinic acid and betulinic acid acetate on human 
myeloid leukemia, HL-60. 
3. To investigate the effect of betulinic acid and betulinic acid acetate on the 
proliferation, morphological changes and mode of cell death on human myeloid 
leukemia, HL-60. 
4. To compare the cytotoxic effect of betulinic acid and betulinic acid acetate with 
the conventional anti-neoplastic drug (doxorubicin). 
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CHAPTER 2 
 
LITERATURE REVIEW  
 
2.1 Cancer  
 
Cancer is a heterogeneous group of diseases, characterized by uncontrolled 
growth of cell population (Griffith et al., 1996). Continuous division of these cells results 
in the formation and growth of tumors. Tumors are classified with reference to a number 
of criteria including their behavior, their appearances and their origins (Evans, 1991). 
Cancer cells escape from many of the normal homeostatic mechanism that control 
proliferation (Goodman, 1994).  
 
Clinical experience indicates that there are two fundamental types of tumors, 
benign and malignant, which behave in different ways (Darnell et al., 1986). Benign 
tumors remain localized and do not spread to different parts of body (Evan, 1991). 
Malignant tumors do not remain localized and encapsulated. They invade surrounding 
tissues, get into the body’s circulating system and set up areas of proliferation away from 
the site of their original appearance (Darnell et al., 1986). 
 
Most tumors contain alterations in both tumor-suppressor genes and oncogenes, 
suggesting that the lost of a tumor-suppressor genes function within a cell must be 
accompanied by the conversion or activation of proto-oncogenes into an oncogene before 
the cell becomes fully malignant (Becker and Deamer, 1991). Proto-oncogenes and 
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tumor-suppressor genes encode many kinds of proteins that help control cell growth and 
proliferation. Mutations in these genes can contribute to the development of cancer 
(Lodish et al., 2000).  
 
Cancerous tumor is the disease of malignant tumors. Malignant tumors or cancer 
are aggregates of cells caused by a series of chromosomal changes. Cancer cells often 
differ from their normal neighbors by a host of specific phenotypic changes, such as rapid 
division rate, invasion of new cellular territories, high metabolic rate and altered shape 
(Griffith et al., 1996). Transformation of normal cells to malignant cells may be triggered 
by several factors including chemical exposure, viruses and radiations. It also can occur 
deliberately under cellular control during the processes such as meiosis or hypermutation 
(Lodish et al., 2000). 
 
Cancers originate within a single cell. Hence, cancers can be classified by the type 
of cell in which it originates and by the location of the cell as carcinomas, 
adenocarcinomas, malignant melanoma, sarcomas, leukemias, lymphomas or 
teratocarcinomas. Carcinomas originate in epithelial cells. Adenocarcinomas originate 
from glandular epithelial tissue. Malignant melanoma arises in melanocytes, a pigmented 
epithelial cell. Sarcoma begins in the connective tissue of bone or muscle. Leukemias 
start in the bone marrow stem cells. Lymphoma is a cancer originating in lymphatic 
tissue. Teratocarcinomas begin within germ cells (Evan, 1991). 
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2.2 Leukemia 
 
Leukemia is a malignant hematopoietic disease characterized by an uncontrolled 
proliferation and block in differentiation of hematopoietic cells (Rowley, 1998). These 
malignant cells can spread to the lymph nodes, spleen, liver and other tissues. Leukemia 
is broadly classified as acute or chronic referring to the type of cell affected and by the 
rate of cell growth, and of myeloid or lymphoid according to the type of cell that is 
multiplying abnormally. Acute leukemia signifying rapidly progressing disease with a 
presence of immature, blast cells, while chronic leukemia, denotes slowly progressing 
disease with more mature and well-differentiated cells. Some chronic leukemia may 
transform into an acute phase as “blast crisis” (Leonard, 1993).  
 
The leukemias are classified in accordance with silent pathological features of the 
abnormal excessive hemopoietic cells (Tariq and John, 2002). They are four major 
subtypes of leukemia and several rare forms. The acute leukemias are divided into acute 
myeloid leukemia (AML) and acute lymphocytic leukemia (ALL). The chronic 
leukemias are divided into chronic myeloid leukemia (CML) and chronic lymphocytic 
leukemia (CLL). Other, rare types of leukemia include hairy cell leukemia, sezary cell 
leukemia, plasma cell leukemia and the leukemia phase of lymphoma (Edward and 
Gregory, 2002). 
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2.2.1 Acute Myeloid Leukemia (AML)  
 
Acute myeloid leukemia (AML) is characterized by the malignant transformation 
of myeloid stem cells in the bone marrow, which are in capable of normal differentiation 
and maturation (Tariq and John, 2002).  This type of leukemia is also referred to as acute 
nonlymphocytic leukemia (ANLL) because nonlymphoid cells are affected (Lowenberg 
et al., 1999). Since the normal hematopoiesis is organized hierarchically, the malignant 
transformation can occur at several levels. AML may arise in a stem cell capable of 
differentiating into cells of erythroid, granulocytic, monocytic and megakaryocytic 
lineages, or in a lineage-restricted stem cell (Tariq and John, 2002).  AML is most 
common cancer among adults between the ages 63 to 65 years (Lowenberg et al., 1999). 
 
Most patients with AML present with signs and symptoms arising from a bone 
marrow failure and organ infiltration by leukemic cells. Occasionally, patients may 
present as a consequence of hyperleucostasis. The diagnosis of AML is made when more 
than 30 per cent of blast cells (myeloblasts) are found in bone marrow or peripheral blood 
(Tariq and John, 2002). This results in anemia, thrombocytopenia and granulocytopenia 
with obvious symptoms such as fatigue, fever, dizziness, infection and bleeding. This 
disease has a very rapid onset. Without treatment, a patient only rarely survives more 
than 6 to 12 months (Ghaddar and Estey 2003).   
 
AML is classically subdivided into subtypes L0 through L7 based on the various 
degrees of differentiation and the lineage of cell maturation using the French-American-
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